Impact assessment of vaccine-related negative news and incentive measures on vaccine hesitancy in Hong Kong

Yifan Chen[1], Yang Ye[2], Hsiang-Yu Yuan[3,4], Qingpeng Zhang[5,6*]

[1]School of Data Science, City University of Hong Kong, Hong Kong, China.

[2]Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, Yale University, New Haven, CT, USA.

[3]Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.

[4]Centre for Applied One Health Research and Policy Advice, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.

[5]Musketeers Foundation Institute of Data Science, The University of Hong Kong, Hong Kong, China.

[6]Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

*qpzhang@hku.hk (https://orcid.org/0000-0002-6819-0686)

Abstract

Vaccine hesitancy underscores the critical need to quantify how diverse factors shape vaccine uptake. We develop a social-epidemiological transmission model with a game-theoretic imitation mechanism and payoff-driven risk perception to assess the impacts of vaccine-related negative news and incentive measures on COVID-19 vaccine uptake during the pandemic. By fitting our model with real-world data from Hong Kong, we reveal that the negative news drastically

impeded vaccination efforts. Scenario analyses suggest that, without incentive measures, the projected fifth wave of COVID-19 in Hong Kong (from December 31, 2021, to October 15, 2022) would have infected 97.3% of the population, resulting in an estimated 48,892 deaths. Both model simulation and real-world data demonstrate that incentive measures have successfully encouraged vaccine uptake and saved approximately 39,073 lives. However, we found that vaccine willingness declined rapidly after the incentive measures discontinued, implying limited benefits in mitigating the effect of negative news in the long run. This study also highlights the need for booster doses in the face of the immune escape of the Omicron variants. Our model offers data-driven insights into the interplay between negative news, vaccine hesitancy, and incentive measures, shedding light on the effective preparation for emerging infectious disease outbreaks.

Introduction

Vaccine hesitancy has been among the top ten global health threats identified by the World Health Organization (WHO)[1]. The ongoing mutations of COVID-19 highlight the need to address vaccine hesitancy, as it can lead to repeated infections and elevate the risk of developing Long COVID[2,3]. Vaccine hesitancy extends beyond COVID-19. Recent WHO statistics indicate that vaccination coverage rates for measles, diphtheria-tetanus-pertussis (DTP), and human papillomavirus (HPV) fall short of established targets[4]. This reluctance to vaccinate undermines the United Nations' Sustainable Development Goal (SDG) of healthy lives and well-being for all at all ages[5]. Addressing vaccine hesitancy is essential for achieving better health outcomes globally.

Vaccine hesitancy is multifactorial, spanning psychological, social, and structural

44 dimensions[6], which can be conceptualized through the 5C scale[7]: *confidence*[8–12] (trust in vaccine
45 safety and efficacy, delivery systems, and governance), *complacency*[13–15] (perceived low risk of
46 disease or lack of urgency to vaccinate), *constraints*[16] (barriers such as cost, access, or logistical
47 limitations), *calculation*[17–19] (active information seeking), and *collective responsibility*[20,21] (the
48 willingness to protect others by one's own vaccination by means of herd immunity).

49 Notably, negative news directly erodes confidence (e.g., safety scandals[10,11,22]) and fuels
50 calculation (e.g., misinformation-driven risk overanalysis[23]). Historical misuse of medical and
51 vaccine research during the colonial era in Africa continues to affect COVID-19 vaccination
52 rates on the continent[24]. Negative news has stronger effects on public trust than positive news,
53 often resulting in greater public engagement[25–27] and the proliferation of conspiracy theories and
54 misinformation[28]. Negative news thrives in polarized environments: right-wing or conservatives
55 exhibit relatively higher susceptibility to conspiracy theories and misinformation[18,29–35], often
56 exacerbating vaccine hesitancy under the governance of right-wing parties or the claim of
57 prominent anti-vaccine activists. Conversely, incentive measures primarily address constraints
58 but may indirectly affect confidence through institutional trust signaling. In Europe, cash
59 incentives were effective in boosting vaccination rates[36]. Interestingly, smaller cash rewards
60 positively affected vaccination rates more than higher cash rewards[37]. However, several studies
61 have shown that negative news regarding the Oxford AstraZeneca vaccine did not affect its
62 uptake in the UK and Denmark[38–40], and economic incentives did not increase overall
63 vaccination rates at all in the United States[41,42]. Additionally, a previous study has indicated that
64 in Hong Kong, the incentive measures have little impact on encouraging older adults to get
65 vaccinated[43].

66 The COVID-19 epidemic in Hong Kong provides an ideal case study, offering a real-life

experimental setting to assess the impact of vaccine-related events on vaccine hesitancy. During the pandemic, the public willingness to get vaccinated declined due to vaccine-related negative news, including packaging defects, serious adverse events after vaccination, and reduced information about deaths possibly linked to vaccination[44–46]. Subsequently, various incentive measures were introduced, including material gifts, economic rewards, and vaccination leave[47]. While many surveys have examined the effects of various factors on vaccine hesitancy in Hong Kong[48–52], predefined surveys often fail to capture all relevant factors and events, and limited sample sizes often lead to selection bias. Thus, understanding these vaccine-related events is crucial for addressing vaccine hesitancy effectively.

In this study, we aim to leverage real epidemiological data to assess the impact of vaccine-related negative news and incentive measures on vaccine hesitancy in Hong Kong. We develop a social-epidemiological model to account for key events affecting vaccine uptake. With this model, we conduct scenario analyses to evaluate how these elements affect the number of infections and deaths.

Results

To evaluate the impact of vaccine-related events on vaccine uptake in Hong Kong, we used a deterministic, SEIRD-like model-based framework to model COVID-19 epidemic dynamics and daily vaccination administration (see Supplementary Fig. 1). This model incorporated time-varying daily vaccination rates modulated by risk perception dynamic, where vaccine uptake is quantified through a composite payoff function comprising three synergistic components: infection risk and mortality risk reduction after vaccination, and vaccine-related events including negative news and incentive measures.

Model-based infection-vaccination dynamics and event-driven behavioral shifts

We explored the impact of vaccine-related negative news and incentive measures on infection-vaccination dynamics in Hong Kong. To do so, we first fitted the social-epidemiological model to daily reported infected cases and count of vaccination in Hong Kong. The study period spanned from January 24, 2020, to October 15, 2022, which was delineated into three phases based on vaccine availability (see the Methods for more details). Our model successfully reproduced the epidemic dynamics and daily vaccination trends across the study period, with reasonable consistency between observed data and model fits (see Fig. 1 for fits; Supplementary Figs. 2-12 for full model diagnostics). Of note, fits were poorer for the booster vaccination phase due to the limitations of segmented modeling (Fig. 1c). These segments were driven by two key events: E1 (February 26, 2022): a sudden surge in reported infected cases because the government included positive RAT (rapid antigen tests) cases in official statistics; E2 (May 23, 2022): the emergence of a new epidemic wave. Nonetheless, the consistency of fits across multiply-independently sampled chains allowed us to reliably assess the impact of vaccine-related events on vaccine uptake in Hong Kong.

We used the estimated payoff gains to quantify how screened critical events influenced people's willingness to get vaccinated (Table 1). The analysis revealed that negative news substantially reduced the perceived benefits of vaccination. Notably, the vaccine packaging defects (E0) led to a reduction in the payoff gain, decreasing it by 232.4% (95% CI: 158.3%-306.5%). This event had a markedly greater impact on vaccination hesitancy compared to the other two events, the serious adverse events after vaccination (T1: 100.7%, 95% CI: 76.6%-124.9%) and reduced information about deaths possibly linked to vaccination (T3: 77.1%, 95% CI: 40.0%-114.2%).



Figure 1. COVID-19 epidemic dynamics and vaccination in Hong Kong (Jan. 2020-Oct. 2022). (a) Daily new reported infected cases (blue circles) and model-fitted transmission trend (red line; 95% CI shaded); (b)-(c) Daily count of vaccination (magenta diamonds) and model-fitted vaccination rates; (d) Zoomed-in view of the marked period in panel a (dashed shaded grey box) showing detailed fitting. Black dotted line in panel b and c show timepoints of fitting segmentation (E0-E2). Gray dashed lines in panel b show timepoints of four critical events (T1-T4).

120 In response to a slow vaccine rollout of COVID-19, the Hong Kong government and local
121 private sectors introduced several incentive measures (T2) to encourage vaccination, including
122 lucky draws and cash bounties, which increased the benefits of receiving primary vaccine doses.
123 However, their effect was temporary, as evidenced by a reduction in payoff gain once these
124 reward programs concluded (T4: 94.6%, 95% CI: 66.1%-123.1%).

125 **Table 1.** The impact of different events on vaccine uptake.

Timepoints of events	Events	Potential 5C scale	Payoff gains for primary vaccination series
2021.03.24	E0: Vaccine packaging defects	Confidence	-130.8(-232.4%)
2021.04.19	T1: Serious adverse events after vaccination	Confidence	-71.9(-100.7%)
2021.05.26	T2: Government and business incentive measures	Constraints, confidence	64.6(90.6%)
2021.06.01	T3: Reduced information about deaths possibly linked to vaccination	Confidence, calculation	-55.0(-77.1%)
2021.08.08	T4: End of the incentive measures	Constraints	-67.5(-94.6%)

126 **Impact of negative news mitigation on vaccination uptake and epidemic trajectories**

127 Our simulations demonstrated how mitigating the effects of negative news can alter vaccination
128 trends and ultimately reduce the public health burden of COVID-19. We simulated the
129 transmission dynamic and daily vaccination rates under four scenarios without incentive
130 measures (Fig. 2): (1) negative news only (the scenario with negative news but without incentive
131 measures; the yellow curve); (2) no news & incentives (the scenario with neither negative news
132 nor incentive measures; the teal curve); (3)-(4) mitigating 50% and 25% of the effects of
133 negative news without incentive measures, respectively (purple and dark brown curves). These

simulations were compared to the actual scenario (red curve) to assess how different levels of negative news influence vaccination rates and transmission dynamics.



Figure 2. COVID-19 epidemic dynamics and vaccination over time under scenarios without incentive measures (primary vaccination series phase). (a) The transmission trend; (b) Vaccination rates. The solid curves and bands represent the mean of fitted or simulated results, and 95% confidence intervals, respectively. The simulated results of scenarios are represented in yellow, teal, purple and dark brown, respectively.

Comparing the "negative news only" scenario with the actual scenario, we found that, without any incentive measures, the daily vaccine uptake could be much lower than that of the actual scenario. Upon the arrival of the Omicron variant, the epidemic would peak earlier than anticipated, with peak daily infections reaching 3.81 times (95% CI: 1.11-6.50) the actual peak. Without the negative news, daily vaccinations would continue to rise until reaching maximum capacity and remain steady until mid-August, achieving the first primary doses vaccination rate

148 of 99.7% by booster dose rollout—56.5% higher than actual figures.

149 With universal primary vaccination doses, the Omicron wave in mid-January 2022 would
150 be averted, substantially reducing infection and mortality rates. However, by late July 2022, a
151 more serious wave of outbreaks would emerge caused by the Omicron mutant strain sub-lineages
152 BA.4/BA.5[53]. In this scenario, the projected cumulative number of infections was approximately
153 4.02 million, which was 2.19 million more than the fitted actual figure. Despite the increase in
154 infected cases, an estimated 5,284 lives would be saved by the study's conclusion.

155 Additionally, we found that without incentive measures, the government must mitigate at
156 least 50% of the negative news impact to achieve high coverage (99.7%) of the population
157 receiving primary doses by booster dose rollout. As a result, the fifth wave of outbreak in Hong
158 Kong (in early 2022) could have been prevented.

159 **The synergistic effect of introducing incentive measures and mitigating negative news**

160 Our simulations demonstrated that combining partial mitigation of negative news with incentive
161 measures substantially enhanced vaccination coverage, but booster dose incentives were critical
162 to countering Omicron immune evasion. We examined how the proper mitigation of negative
163 news may affect the daily infection and vaccination rates under three scenarios with incentive
164 measures (Fig. 3): (1) incentive measures only (the scenario without negative news but with
165 incentive measures; the yellow curve); (2)-(3) mitigating 10% and 5% of the impact of negative
166 news with incentive measures, respectively (since incentive measures can compensate for
167 approximately 50.9% of the impact of negative news, shown in Table 1).

168 In both the scenarios "no news & incentives" and "incentive measures only", the daily
169 vaccine uptake shared a similar pattern regardless of the incentive measures (as shown by the

yellow and teal curves in Fig. 3). Importantly, introducing incentive measures could effectively reduce vaccine hesitancy so that as little as 5% negative news mitigation was sufficient to prevent the fifth outbreak. However, merely increasing the vaccination rate of the two primary doses was insufficient to prevent the future outbreak due to the immune escape of the Omicron variants and the low booster dose vaccine uptake (Fig. 3a, Aug. 2022).



Figure 3. COVID-19 epidemic dynamics and vaccination over time (primary vaccination series phase). (a)-(b) The transmission trend and vaccination rates under four scenarios. The solid curves and bands represent the mean of fitted or simulated results, and 95% confidence intervals, respectively. The simulated results of scenarios are represented in yellow, teal, purple and dark brown, respectively.

To address this challenge, we simulated how the incentive measures for booster doses to

182 contain the future outbreak. The results showed that if small- to medium-level (25% to 50%)
183 incentive measures were introduced for booster doses after the primary doses vaccination
184 program, the future Omicron-led outbreak could be curbed, potentially reducing infections by 6.4
185 million and saving 4,748 lives throughout the study period, compared with a scenario without
186 any incentive measures for booster doses (Fig. 4).



187

188 **Figure 4.** COVID-19 epidemic dynamics over time (booster vaccination phase). The
189 transmission trend under three scenarios. The solid curves and bands represent the mean of fitted
190 or simulated results, and 95% confidence intervals, respectively. The simulated results of
191 scenarios are represented in teal, dark brown and light blue, respectively.

192 Discussion

193 In our study, we fit real epidemic dynamic data to understand how vaccine-related events
194 influenced vaccine uptake in Hong Kong. Our research offers evidence and insights, highlighting
195 the positive synergistic effect of managing negative news and introducing incentive measures to
196 achieve herd immunity. We recommend that only modest incentive measures for booster doses
197 are sufficient to control outbreaks caused by immune escape.

198 This study provides data-driven evidence for previous survey studies[49–51,54], assessing the

199 importance of specific vaccine-related events, including the impact of negative news and
200 incentive measures on vaccine uptake. Negative news may reduce vaccination willingness
201 through dual pathways: *confidence* (reports of adverse events and packaging defects reduced
202 trust in vaccine safety, which is a primary concern across all age groups in Hong Kong[49]) and
203 *calculation* (reduced information about deaths prolonged risk-benefit analysis). Negative news
204 may directly undermine trust in the government and contribute to the spread of misinformation
205 and rumors, which has been shown further to amplify vaccine hesitancy through compounded
206 psychological and social mechanisms[55]. Mitigating the effects of negative news by 50% can
207 achieve high coverage of the first two primary doses and save costs on incentive measures,
208 allowing resources to be reallocated toward increasing vaccine supply, expanding healthcare
209 capacity, and supporting economic growth. Notably, previous research has shown that providing
210 information about vaccine risks does not influence willingness to vaccinate[56,57]. Our results
211 suggest that the timely, proper, and transparent publicity of pandemic and vaccine safety-related
212 information could boost vaccination rates by mitigating misinformation originating from
213 negative news. Our findings show that incentive measures may compensate 50.9% of negative
214 news's impact through *constraints* to boost vaccine uptake. Ultimately, it will aid in the faster
215 achievement of herd immunity and minimize unnecessary infections and deaths. However, their
216 effects are short-term, and vaccine hesitancy remains slightly increased after the incentive
217 measures end.

218 Our results shed light on the fact that even with high vaccine coverage of first primary
219 doses, neglecting booster doses could lead to a stronger outbreak of Omicron in Hong Kong. The
220 principle underlying the outbreak is the accumulation of susceptible individuals and the
221 relaxation of PHSMs, which aligns with our previous research on respiratory infectious

222 diseases[58,59]. In addition, the Omicron BA.4/BA.5 resurgence despite high primary dosing further
223 highlights *complacency*'s role in the low infection phase, which implicated waning variant
224 vigilance. Thus, when addressing future virus spread and vaccine promotion, the government
225 should not only focus on current epidemic dynamics but also consider virus characteristics to
226 develop seamless and comprehensive strategies. Fortunately, we observed that minimal incentive
227 measures for booster doses can prevent this outbreak. The synergistic effect of combining
228 incentive measures and negative news mitigation indicates a cost-effective approach to
229 promoting vaccination programs during an epidemic.

230 Our research has limitations. First, our study's timeframe was limited to data available up to
231 October 15, 2022, due to the availability of Google Mobility data. It is important to identify
232 alternative public human mobility data for future epidemic surveillance and modeling. Second,
233 this study did not explore how negative news and incentive measures affect different
234 socioeconomic groups. A study has indicated that in Hong Kong, incentive measures have little
235 impact on encouraging older adults to get vaccinated[43]. Our model is flexible and can be easily
236 extended to account for the composition of different subpopulations, aiding the formulation of
237 more targeted policy measures. It is important to explore age-specific responses to these key
238 events given representative survey data. Third, our study focused on data from Hong Kong. To
239 expand our research to other regions, we would require relevant epidemic data and event
240 information from each area. However, some regions lack available data, which limits our study
241 to Hong Kong. Nonetheless, our model can be easily adjusted to evaluate vaccine-related events
242 in different regions, helping them develop vaccination strategies suited to their specific needs.

243 In summary, our research assessed the effects of negative news and incentive measures on
244 vaccine willingness during the COVID-19 crisis. We highlighted the importance of mitigating

245 the impact of negative news and the positive effect of incentive measures on increasing vaccine
246 uptake. Our model can be adapted to various national and regional contexts, making it a valuable
247 tool for evaluating certain events. It also offers scalability to address future outbreaks, providing
248 the government with valuable insights to effectively promote vaccines in response to different
249 viral threats.

250 Methods

251 Data Source

252 We obtained daily reported COVID-19 infected cases (January 24, 2020, to October 15, 2022)
253 and vaccination doses (February 26, 2021, to October 15, 2022) from the DATA.GOV.HK
254 database[60]. According to the availability of vaccines, we divided the Hong Kong epidemic into
255 three phases based on the vaccination plan: (1) pre-vaccination phase; from January 24, 2020, to
256 February 25, 2021, during which the Hong Kong government relied solely on PHSMs to control
257 the epidemic; (2) primary vaccination series phase; from February 26, 2021, to November 10,
258 2021, during which citizens could begin receiving the first two primary doses of Sinovac and
259 BioNTech vaccines in addition to PHSMs; (3)booster vaccination phase; from November 11,
260 2021, to October 15, 2022, during which citizens could start receiving booster doses of the
261 vaccine. We exclusively focused on locally acquired infections to isolate local transmission
262 dynamics under Hong Kong's stringent border quarantine policies. Five case categories -
263 *epidemiologically linked with local case, epidemiologically linked with possibly local case, local*
264 *case, locally acquired case, and possibly local case* – were consolidated into a unified *local*
265 *transmission* category. A 7-day moving average was applied to mitigate reporting delays and
266 weekday fluctuations in case counts. We aggregated Sinovac (CoronaVac) and BioNTech

267 (Comirnaty) recipients for vaccination data, assuming comparable vaccine efficacy between the
268 two vaccines. The contact matrix in Hong Kong was projected using empirical data from the
269 COVID-19 era[61]. Additionally, daily mobility trends during the study period were extracted from
270 Google community mobility reports[56]. We used the average changes in *retail and recreation*
271 *percent change from baseline* and *transit stations percent change from baseline* to represent the
272 extent of mobility changes in Hong Kong under different PHSMs implementations during the
273 epidemic.

274 **Model Structure**

275 We proposed a social-epidemiological transmission model based on the SEVPIRD-CT
276 framework (susceptible, exposed, vaccinated, presymptomatic, infected, recovered, deceased,
277 contact-traced), as illustrated in Supplementary, Fig. 1. Susceptible individuals enter an exposed
278 (E) state upon infection, characterized by a latent period with no infectiousness. Following
279 latency, they transition to a presymptomatic (P) state, becoming infectious but remaining
280 asymptomatic. Presymptomatic individuals are either identified via contact tracing (CT) and
281 isolated upon symptom onset or progress to the infected (I) state, with eventual transition to
282 recovered (R) or deceased (D) compartments.

283 During the phase of vaccination programs, susceptible individuals move to a vaccinated (V)
284 state upon immunization. Breakthrough infections in vaccinated individuals follow the same
285 progression $(E \rightarrow P \rightarrow I \rightarrow R/D)$ but with reduced mortality rates calibrated to vaccine
286 efficacy. We incorporated imitation dynamics reflecting social learning processes to capture
287 temporal shifts in vaccine uptake behavior. The daily vaccination willingness (y^H) evolves
288 according to:

$$\frac{dy^H}{dt} = \kappa^H y^H (1 - y^H) \left[(\beta^{H_0} - \beta^H) + r_{CFR}^H (CFR^{H_0} - CFR^H) + \Psi_{baseline} + \sum \Psi_{Events} \right]$$

where y represents the proportion of individuals vaccinated daily based on the daily maximum appointment vaccination capacity. H_0 and H act paired vaccination status (e.g., H_0 = unvaccinated, H = fully vaccinated; H_0 = fully vaccinated, H = received a booster dose). κ denotes the imitation rate at which individuals sample others and switch vaccinating behavior, while β and CFR stand for the transmission rate and case fatality rate of administering the dose H_0 or H. r is the adjustment coefficient for the difference in case fatality rates. Ψ_{Events} signifies the payoff gain following different vaccine-related events. The aggregated value of terms within the square brackets quantifies population-level risk perception, whereby the algebraic sign (positive/negative) governs the behavioral inclination toward vaccination—positive values amplify vaccine uptake through perceived benefit dominance, while negative values suppress it via risk aversion dominance.

Statistical Analysis

We fitted the daily reported cases for each wave of the epidemic in Hong Kong, as well as the daily number of vaccinations during the vaccination program implementation period, using MCMC methods with the MCMCstat toolbox[64]. The model parameter values for each epidemic wave are presented in Supplementary Table 1. We randomly generated 10,000 sets of parameters using Latin Hypercube Sampling (LHS). After running all parameter sets, we selected the three sets with the most minor errors as our initial parameter sets.

For fitting each phase, we further divided each phase into segments based on the number of epidemic waves and the occurrence of certain events. For the first segment fitting, we assumed that an individual in the presymptomatic stage entered a population entirely susceptible to

311 infection. The initial values for fitting each subsequent segment were set as the ending values of
312 the previous segment. We used the Poisson likelihood function as the loss function for daily
313 reported cases and vaccination numbers.

314 Finally, we estimated the convergence of the MCMC chains using the Gelman-Rubin
315 diagnostic. Once the MCMC chains converged and stabilized, we randomly selected 500
316 parameter sets from the burn-in phase (half the chain length) to generate 95% confidence
317 intervals based on these 500 parameter sets.

318 **Events Screening**

319 A previous study surveyed Hong Kong to determine reasons for vaccine hesitancy across
320 different age groups[49]. After excluding personal factors like concerns about chronic diseases,
321 already antibodies, and lack of social norms or support, the top three reasons were identified for
322 each group. These reasons were then grouped into vaccine-specific issues, low trust in the
323 government, and a lack of urgency or perceived need for vaccination. To select relevant events,
324 we applied polynomial fitting to daily vaccination data to find inflection points in the rate
325 changes. These were identified on April 19, May 13, June 30, July 15, August 5, October 27, and
326 November 7, 2021. Considering the lead or lag time of events[65], related news was reviewed from
327 the Department of Health press releases[66] and the Oriental Daily News[67] within 28 days before
328 and after these dates. The events listed in Table 1 were then chosen, and their impact on vaccine
329 hesitancy in Hong Kong was measured.

330 **Data availability**

331 Data of COVID-19 reported cases, death numbers and count of vaccination were retrieved from

official source (https://data.gov.hk/en-data/dataset/hk-dh-chpsebcddr-novel-infectious-agent (2023) and https://data.gov.hk/en-data/dataset/hk-hhb-hhbcovid19-vaccination-rates-over-time-by-age (2023)). Mobility changes were retrieved from (https://www.google.com/covid19/mobility/)

Code availability

The fitting and analysis codes are publicly available at https://github.com/yifan7-chen/Vaccine_Hesitancy

References

1. World Health Organization. Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.
2. COVID-19 Real-Time Learning Network. COVID-19 Variant Update. https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/covid-19-variant-update/#/+/0/publishedDate_na_dt/desc/.
3. Centers for Disease Control and Prevention. Long COVID. https://www.cdc.gov/covid/long-term-effects/index.html.
4. United Nations International Children's Emergency Fund. Immunization. https://data.unicef.org/topic/child-health/immunization/ (2024).
5. United Nations. The 17 Sustainable Development Goals. https://sdgs.un.org/goals.
6. MacDonald, N. E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* **33**, 4161–4164 (2015).
7. Betsch, C. *et al.* Beyond confidence: Development of a measure assessing the 5C

353 psychological antecedents of vaccination. *PLOS ONE* **13**, e0208601 (2018).

354 8. Soares, P. *et al.* Factors Associated with COVID-19 Vaccine Hesitancy. *Vaccines* **9**, 300
355 (2021).

356 9. Prickett, K. C., Habibi, H. & Carr, P. A. COVID-19 Vaccine Hesitancy and Acceptance in a
357 Cohort of Diverse New Zealanders. *Lancet Reg. Health - West. Pac.* **14**, 100241 (2021).

358 10. Solís Arce, J. S. *et al.* COVID-19 vaccine acceptance and hesitancy in low- and middle-
359 income countries. *Nat. Med.* **27**, 1385–1394 (2021).

360 11. Schmid, P., Rauber, D., Betsch, C., Lidolt, G. & Denker, M.-L. Barriers of Influenza
361 Vaccination Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy,
362 2005 – 2016. *PLOS ONE* **12**, e0170550 (2017).

363 12. Rane, M. S. *et al.* Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine
364 Uptake in a National Cohort of US Adults: A Longitudinal Study. *Am. J. Epidemiol.* **191**,
365 570–583 (2022).

366 13. Caserotti, M. *et al.* Associations of COVID-19 risk perception with vaccine hesitancy over
367 time for Italian residents. *Soc. Sci. Med.* **272**, 113688 (2021).

368 14. Ghaznavi, C. *et al.* Factors associated with reversals of COVID-19 vaccination willingness:
369 Results from two longitudinal, national surveys in Japan 2021-2022. *Lancet Reg. Health -*
370 *West. Pac.* **27**, 100540 (2022).

371 15. Peterson, P., McNabb, P., Maddali, S. R., Heath, J. & Santibañez, S. Engaging Communities
372 to Reach Immigrant and Minority Populations: The Minnesota Immunization Networking
373 Initiative (MINI), 2006-2017. *Public Health Rep.* **134**, 241–248 (2019).

374 16. Sato, R. & Fintan, B. Effect of cash incentives on tetanus toxoid vaccination among rural
375 Nigerian women: a randomized controlled trial. *Hum. Vaccines Immunother.* **16**, 1181–1188

376 (2020).
377 17. Freeman, D. *et al.* COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus
378 explanations, attitudes, and narratives survey (Oceans) II. *Psychol. Med.* **52**, 3127–3141
379 (2022).
380 18. Fridman, A., Gershon, R. & Gneezy, A. COVID-19 and vaccine hesitancy: A longitudinal
381 study. *PLOS ONE* **16**, e0250123 (2021).
382 19. Loomba, S., De Figueiredo, A., Piatek, S. J., De Graaf, K. & Larson, H. J. Measuring the
383 impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. *Nat.*
384 *Hum. Behav.* **5**, 337–348 (2021).
385 20. Duncan, L. *et al.* Factors Affecting Parental Intent to Vaccinate Against COVID-19 in the
386 United States. *Kans. J. Med.* **17**, 51–56 (2024).
387 21. Dror, A. A. *et al.* Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur.*
388 *J. Epidemiol.* **35**, 775–779 (2020).
389 22. Schwarzinger, M., Watson, V., Arwidson, P., Alla, F. & Luchini, S. COVID-19 vaccine
390 hesitancy in a representative working-age population in France: a survey experiment based
391 on vaccine characteristics. *Lancet Public Health* **6**, e210–e221 (2021).
392 23. Pertwee, E., Simas, C. & Larson, H. J. An epidemic of uncertainty: rumors, conspiracy
393 theories and vaccine hesitancy. *Nat. Med.* **28**, 456–459 (2022).
394 24. Mutombo, P. N. *et al.* COVID-19 vaccine hesitancy in Africa: a call to action. *Lancet Glob.*
395 *Health* **10**, e320–e321 (2022).
396 25. Hou, Z. *et al.* Assessing COVID-19 Vaccine Hesitancy, Confidence, and Public Engagement:
397 A Global Social Listening Study. *J. Med. Internet Res.* **23**, e27632 (2021).
398 26. Zhang, Q., Zhang, R., Wu, W., Liu, Y. & Zhou, Y. Impact of social media news on COVID-

399 19 vaccine hesitancy and vaccination behavior. *Telemat. Inform.* **80**, 101983 (2023).

400 27. Siegrist, M. & Zingg, A. The Role of Public Trust During Pandemics: Implications for Crisis
401 Communication. *Eur. Psychol.* **19**, 23–32 (2014).

402 28. Rief, W. Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of
403 the Treatment Expectation Expert Group. *JAMA Health Forum* **2**, e210804 (2021).

404 29. Hornsey, M. J., Finlayson, M., Chatwood, G. & Begeny, C. T. Donald Trump and
405 vaccination: The effect of political identity, conspiracist ideation and presidential tweets on
406 vaccine hesitancy. *J. Exp. Soc. Psychol.* **88**, 103947 (2020).

407 30. De Munter, A. C. *et al.* Determinants of HPV-vaccination uptake and subgroups with a lower
408 uptake in the Netherlands. *BMC Public Health* **21**, 1848 (2021).

409 31. Kannan, V. D. & Veazie, P. J. Political orientation, political environment, and health
410 behaviors in the United States. *Prev. Med.* **114**, 95–101 (2018).

411 32. Stoeckel, F., Carter, C., Lyons, B. A. & Reifler, J. The politics of vaccine hesitancy in
412 Europe. *Eur. J. Public Health* **32**, 636–642 (2022).

413 33. Jones, D. R. & McDermott, M. L. Partisanship and the Politics of COVID Vaccine
414 Hesitancy. *Polity* **54**, 408–434 (2022).

415 34. Bilewicz, M. & Soral, W. The Politics of Vaccine Hesitancy: An Ideological Dual-Process
416 Approach. *Soc. Psychol. Personal. Sci.* **13**, 1080–1089 (2022).

417 35. Hotez, P. J. America's deadly flirtation with antiscience and the medical freedom movement.
418 *J. Clin. Invest.* **131**, e149072 (2021).

419 36. Kuznetsova, L., Diago-Navarro, E., Mathu, R. & Trilla, A. Effectiveness of COVID-19
420 Vaccination Mandates and Incentives in Europe. *Vaccines* **10**, 1714 (2022).

421 37. Duch, R. *et al.* Financial incentives for COVID-19 vaccines in a rural low-resource setting: a

422 cluster-randomized trial. *Nat. Med.* **29**, 3193–3202 (2023).

423 38. Comerford, D. *et al.* Did Negative News Regarding the Oxford AstraZeneca Vaccine end in
424 Vaccine Hesitancy? A Repeated Cross-Section Event Study from the UK. Preprint at
425 https://doi.org/10.21203/rs.3.rs-355311/v1 (2021).

426 39. De Albuquerque Veloso Machado, M., Roberts, B., Wong, B. L. H., Van Kessel, R. &
427 Mossialos, E. The Relationship Between the COVID-19 Pandemic and Vaccine Hesitancy: A
428 Scoping Review of Literature Until August 2021. *Front. Public Health* **9**, 747787 (2021).

429 40. Sønderskov, K. M., Dinesen, P. T. & Østergaard, S. D. Sustained COVID-19 vaccine
430 willingness after safety concerns over the Oxford-AstraZeneca vaccine.

431 41. Thirumurthy, H., Milkman, K. L., Volpp, K. G., Buttenheim, A. M. & Pope, D. G.
432 Association between statewide financial incentive programs and COVID-19 vaccination
433 rates. *PLOS ONE* **17**, e0263425 (2022).

434 42. Jacobson, M., Chang, T. Y., Shah, M., Pramanik, R. & Shah, S. B. Can financial incentives
435 and other nudges increase COVID-19 vaccinations among the vaccine hesitant? A
436 randomized trial. *Vaccine* **40**, 6235–6242 (2022).

437 43. Wang, Z., Fang, Y., Yu, F., Chan, P. S. & Chen, S. Governmental Incentives, Satisfaction
438 with Health Promotional Materials, and COVID-19 Vaccination Uptake among Community-
439 Dwelling Older Adults in Hong Kong: A Random Telephone Survey. *Vaccines* **10**, 732
440 (2022).

441 44. The Government of the Hong Kong Special Administrative Region. Suspension of BioNTech
442 vaccination. https://www.info.gov.hk/gia/general/202103/24/P2021032400357.htm (2021).

443 45. Kwan, R. How Hong Kong's vaccination missteps led to the world's highest covid-19 death
444 rate. *BMJ* o1127 (2022) doi:10.1136/bmj.o1127.

445 46. The Government of the Hong Kong Special Administrative Region. Expert Committee on
446 Clinical Events Assessment Following COVID-19 Immunisation assesses serious adverse
447 events relating to COVID-19 vaccination.
448 https://www.info.gov.hk/gia/general/202106/01/P2021060100985.htm?fontSize=1 (2021).
449 47. The Government of the Hong Kong Special Administrative Region. Vaccine incentives in
450 place. https://www.news.gov.hk/eng/2021/06/20210609/20210609_153435_666.html.
451 48. Du, Z. *et al.* Pandemic fatigue impedes mitigation of COVID-19 in Hong Kong. *Proc. Natl.*
452 *Acad. Sci.* **119**, e2213313119 (2022).
453 49. Yuan, J. *et al.* Dynamic predictors of COVID-19 vaccination uptake and their
454 interconnections over two years in Hong Kong. *Nat. Commun.* **15**, 290 (2024).
455 50. Siu, J. Y., Cao, Y. & Shum, D. H. K. Perceptions of and hesitancy toward COVID-19
456 vaccination in older Chinese adults in Hong Kong: a qualitative study. *BMC Geriatr.* **22**, 288
457 (2022).
458 51. Xiao, J. *et al.* Temporal changes in factors associated with COVID-19 vaccine hesitancy and
459 uptake among adults in Hong Kong: Serial cross-sectional surveys. *Lancet Reg. Health -*
460 *West. Pac.* **23**, 100441 (2022).
461 52. Leung, C. L. K. *et al.* Temporal variations of vaccine hesitancy amid the COVID-19
462 outbreaks in Hong Kong. *Appl. Psychol. Health Well-Being* **16**, 216–234 (2024).
463 53. The Government of the Hong Kong Special Administrative Region. Government explains
464 isolation and quarantine arrangement for COVID-19 cases and close contacts involving sub-
465 lineages of Omicron mutant strain.
466 https://www.info.gov.hk/gia/general/202206/01/P2022060100846.htm (2022).
467 54. Yu, B., Li, Q., Chen, J. & He, D. The impact of COVID-19 vaccination campaign in Hong

Kong SAR China and Singapore. *Infect. Dis. Model.* **8**, 101–106 (2023).

55. Miyachi, T., Takita, M., Senoo, Y. & Yamamoto, K. Lower trust in national government links to no history of vaccination. *The Lancet* **395**, 31–32 (2020).
56. Thorpe, A. *et al.* Communicating about COVID-19 vaccine development and safety. *PLOS ONE* **17**, e0272426 (2022).
57. Bak-Coleman, J. B. *et al.* Combining interventions to reduce the spread of viral misinformation. *Nat. Hum. Behav.* (2022) doi:10.1038/s41562-022-01388-6.
58. Yao, Y., Zhou, H., Cao, Z., Zeng, D. D. & Zhang, Q. Optimal adaptive nonpharmaceutical interventions to mitigate the outbreak of respiratory infections following the COVID-19 pandemic: a deep reinforcement learning study in Hong Kong, China. *J. Am. Med. Inform. Assoc.* **30**, 1543–1551 (2023).
59. Cheng, W. *et al.* Future trajectory of respiratory infections following the COVID-19 pandemic in Hong Kong. *Chaos Interdiscip. J. Nonlinear Sci.* **33**, 013124 (2023).
60. Hong Kong. Open Data Portal. https://data.gov.hk/en/.
61. Prem, K. *et al.* Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. *PLOS Comput. Biol.* **17**, e1009098 (2021).
62. COVID-19 Community Mobility Reports. https://www.google.com/covid19/mobility/.
63. Apple Maps Mobility Trends Reports. https://covid19.apple.com/mobility.
64. MCMC toolbox for Matlab. https://mjlaine.github.io/mcmcstat/.
65. Li, Y. *et al.* The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. *Lancet Infect. Dis.* **21**, 193–202 (2021).

66. Department of Health. Press Release. https://www.dh.gov.hk/english/press/press.html.
67. Oriental Daily News. Former Oriental Daily. https://orientaldaily.on.cc/section/archive.

Acknowledgements

This work was supported in part by the Research Grants Council of the Hong Kong Special Administrative Region, China (Ref. No. 11218221, C7154-20GF, C7151-20GF and C1143-20GF to Q.Z.), and in part by the Health and Medical Research Fund (Ref. No: COVID190215 to H.-Y.Y. and Q.Z.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions

Q.Z. and Y.Y. designed and oversaw the study. Y.C. contributed to data collection, data analysis and data interpretation under the supervision of Q.Z. Y.C wrote the manuscript. Y.Y contributed to revising the manuscript. Q.Z. and H.Y.Y contributed to the interpretation of the findings and revising the manuscript. All authors approved the submitted version and have contributed to the final version of this manuscript.

Competing interests

The authors declare no competing interests.

Figure legends

Figure 1. COVID-19 epidemic dynamics and vaccination in Hong Kong (Jan. 2020-Oct. 2022). (a) Daily new reported infected cases (blue circles) and model-fitted transmission trend (red line; 95% CI shaded); (b)-(c) Daily count of vaccination (magenta diamonds) and model-fitted vaccination rates; (d) Zoomed-in view of the marked period in panel a (dashed shaded grey box) showing detailed fitting. Black dotted line in panel b and c show timepoints of fitting segmentation (E0-E2). Gray dashed lines in panel b show timepoints of four critical events (T1-T4).

Figure 2. COVID-19 epidemic dynamics and vaccination over time under scenarios without incentive measures (primary vaccination series phase). (a) The transmission trend; (b) Vaccination rates. The solid curves and bands represent the mean of fitted or simulated results, and 95% confidence intervals, respectively. The simulated results of scenarios are represented in yellow, teal, purple and dark brown, respectively.

Figure 3. COVID-19 epidemic dynamics and vaccination over time (primary vaccination series phase). (a)-(b) The transmission trend and vaccination rates under four scenarios. The solid curves and bands represent the mean of fitted or simulated results, and 95% confidence intervals, respectively. The simulated results of scenarios are represented in yellow, teal, purple and dark brown, respectively.

Figure 5. COVID-19 epidemic dynamics over time (booster vaccination phase). The transmission trend under three scenarios. The solid curves and bands represent the mean of fitted or simulated results, and 95% confidence intervals, respectively. The simulated results of scenarios are represented in teal, dark brown and light blue, respectively.

Tables

531 **Table 1.** The impact of different events on vaccine uptake.

Timepoints of events	Events	Potential 5C scale	Payoff gains for primary vaccination series
2021.03.24	E0: Vaccine packaging defects	Confidence	-130.8(-232.4%)
2021.04.19	T1: Serious adverse events after vaccination	Confidence	-71.9(-100.7%)
2021.05.26	T2: Government and business incentive measures	Constraints, confidence	64.6(90.6%)
2021.06.01	T3: Reduced information about deaths possibly linked to vaccination	Confidence, calculation	-55.0(-77.1%)
2021.08.08	T4: End of the incentive measures	Constraints	-67.5(-94.6%)

532 **Figures**

533 **Fig. 1.**


Initial two-dose rollout
Booster dose rollout
a
Daily infected cases
100k
80k
60k
40k
20k
0
24-Jan 2020
23-Jul
20-Jan 2021
20-Jul
17-Jan 2022
17-Jul
15-Oct
b
Daily vaccination (primary vaccination series)
E0
T1
T2
T3
T4
60k
45k
30k
15k
0
26-Feb 2021
20-Jul
17-Jan 2022
17-Jul
15-Oct
Fitted
Daily reported infected cases
Daily count of vaccination
Confidence interval (95%)
c
Daily vaccination (booster vaccination)
E1
E2
60k
45k
30k
15k
0
11-Nov 2021
17-Jan 2022
17-Jul
15-Oct
d
Daily infected cases (Pre-booster vaccination)
250
150
50
24-Jan 2020
12-Jun
30-Oct
19-Mar 2021
06-Aug
10-Nov

Fig. 2.



536

537 **Fig. 3.**



538

539 **Fig. 4.**


10k
30
20
10
0
Daily infected cases
(booster vaccination)
11-Nov
2021
18-Jan
2022
27-Mar
03-Jun
10-Aug
15-Oct
Fitted
No negative news
& no incentive measures
No negative news & 25%, 50%
incentive measures for booster doses
Confidence Interval (95%)